{"id":9394,"date":"2026-05-17T15:42:41","date_gmt":"2026-05-17T13:42:41","guid":{"rendered":"https:\/\/fhu-premimpact.org\/?post_type=publication&p=9394"},"modified":"2026-06-05T15:47:36","modified_gmt":"2026-06-05T13:47:36","slug":"procalcitonin-guided-decision-and-antibiotic-treatment-duration-in-late-onset-sepsis-of-newborns-multicentre-randomised-controlled-trial-proabis","status":"publish","type":"publication","link":"https:\/\/fhu-premimpact.org\/en\/publications\/procalcitonin-guided-decision-and-antibiotic-treatment-duration-in-late-onset-sepsis-of-newborns-multicentre-randomised-controlled-trial-proabis\/","title":{"rendered":"Procalcitonin-guided decision and antibiotic treatment duration in late onset sepsis of newborns: multicentre, randomised controlled trial (ProABIS)"},"content":{"rendered":"\n

Abstract<\/h3>\n\n\n\n

Objective:<\/strong> To assess whether procalcitonin-guided decision making can safely reduce the duration of antibiotic treatment in neonatal late onset sepsis.<\/p>\n\n\n\n

Design:<\/strong> Prospective multicentre, randomised open label trial.<\/p>\n\n\n\n

Setting:<\/strong> 33 level 3 and level 2B neonatology departments in France.<\/p>\n\n\n\n

Participants:<\/strong> Newborn babies born after 24 weeks’ gestation, of postconceptional age 24-45 weeks and after 4 days of life, weighing more than 700 g, with suspected or proven late onset sepsis, requiring antibiotics for more than 48 hours, and without meningitis, septic shock, and deep-seated infection.<\/p>\n\n\n\n

Interventions:<\/strong> Participants were randomly assigned to procalcitonin-guided or usual care antibiotic treatment. In the procalcitonin-guided group, procalcitonin concentration was measured at randomisation and then every two days. A non-binding recommendation to discontinue antibiotics was given if the procalcitonin concentration was 0.5 \u00b5g\/L or lower. In the usual care group, treatment was provided according to local protocols.<\/p>\n\n\n\n

Main outcome measures:<\/strong> The primary outcome was the duration of antibiotic treatment (under the superiority hypothesis). The key secondary outcome was non-inferiority for mortality (margin 3%) at day 28 after randomisation.<\/p>\n\n\n\n

Results:<\/strong> Between February 2019 and February 2023, 248 newborns were randomised to the procalcitonin-guided group and 256 to the usual care group. In the intention-to-treat analysis, the median duration of antibiotic treatment was eight days (interquartile range (IQR) 5.0-12.0) in the procalcitonin-guided group versus 10 days (8.0-13.0) in the usual care group (absolute difference between groups -2.0 (IQR -3.8 to -1.0), P<0.001). At day 28, the proportion of death was six of 248 newborns (2.4%) in the procalcitonin-guided group versus 10 of 256 (3.9%) in the usual care group (absolute difference between groups -1.5% (95% confidence interval (CI) -5.0 to 1.8). The proportion of recurrence was seven of 248 (2.8%) newborns in the procalcitonin-guided group versus 10 (3.9%) of 256 in the usual care group (absolute difference between groups -1.1% (95% CI -4.6 to 2.3).<\/p>\n\n\n\n

Conclusion:<\/strong> In this study population, the use of procalcitonin significantly reduced the duration of antibiotic treatment in neonatal late onset sepsis, without increasing mortality or serious adverse events.<\/p>\n\n\n\n

Trial registration:<\/strong> NCT03730636<\/a>.<\/p>\n\n\n\n

Keywords:<\/strong> Intensive care units, neonatal; Neonatology.<\/p>\n","protected":false},"excerpt":{"rendered":"

Abstract Objective: To assess whether procalcitonin-guided decision making can safely reduce the duration of antibiotic treatment in neonatal late onset sepsis. Design: Prospective multicentre, randomised open label trial. Setting: 33 level 3 and level 2B neonatology departments in France. Participants: Newborn babies born after 24 weeks’ gestation, of postconceptional age 24-45 weeks and after 4 […]<\/p>\n","protected":false},"featured_media":0,"template":"","class_list":["post-9394","publication","type-publication","status-publish","hentry"],"yoast_head":"\nProcalcitonin-guided decision and antibiotic treatment duration in late onset sepsis of newborns: multicentre, randomised controlled trial (ProABIS) - FHU Prem'IMPACT<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/fhu-premimpact.org\/en\/publications\/procalcitonin-guided-decision-and-antibiotic-treatment-duration-in-late-onset-sepsis-of-newborns-multicentre-randomised-controlled-trial-proabis\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Procalcitonin-guided decision and antibiotic treatment duration in late onset sepsis of newborns: multicentre, randomised controlled trial (ProABIS) - FHU Prem'IMPACT\" \/>\n<meta property=\"og:description\" content=\"Abstract Objective: To assess whether procalcitonin-guided decision making can safely reduce the duration of antibiotic treatment in neonatal late onset sepsis. Design: Prospective multicentre, randomised open label trial. Setting: 33 level 3 and level 2B neonatology departments in France. Participants: Newborn babies born after 24 weeks’ gestation, of postconceptional age 24-45 weeks and after 4 […]\" \/>\n<meta property=\"og:url\" content=\"https:\/\/fhu-premimpact.org\/en\/publications\/procalcitonin-guided-decision-and-antibiotic-treatment-duration-in-late-onset-sepsis-of-newborns-multicentre-randomised-controlled-trial-proabis\/\" \/>\n<meta property=\"og:site_name\" content=\"FHU Prem'IMPACT\" \/>\n<meta property=\"article:modified_time\" content=\"2026-06-05T13:47:36+00:00\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data1\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/fhu-premimpact.org\\\/en\\\/publications\\\/procalcitonin-guided-decision-and-antibiotic-treatment-duration-in-late-onset-sepsis-of-newborns-multicentre-randomised-controlled-trial-proabis\\\/\",\"url\":\"https:\\\/\\\/fhu-premimpact.org\\\/en\\\/publications\\\/procalcitonin-guided-decision-and-antibiotic-treatment-duration-in-late-onset-sepsis-of-newborns-multicentre-randomised-controlled-trial-proabis\\\/\",\"name\":\"Procalcitonin-guided decision and antibiotic treatment duration in late onset sepsis of newborns: multicentre, randomised controlled trial (ProABIS) - FHU Prem'IMPACT\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/fhu-premimpact.org\\\/en\\\/#website\"},\"datePublished\":\"2026-05-17T13:42:41+00:00\",\"dateModified\":\"2026-06-05T13:47:36+00:00\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/fhu-premimpact.org\\\/en\\\/publications\\\/procalcitonin-guided-decision-and-antibiotic-treatment-duration-in-late-onset-sepsis-of-newborns-multicentre-randomised-controlled-trial-proabis\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/fhu-premimpact.org\\\/en\\\/publications\\\/procalcitonin-guided-decision-and-antibiotic-treatment-duration-in-late-onset-sepsis-of-newborns-multicentre-randomised-controlled-trial-proabis\\\/\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/fhu-premimpact.org\\\/en\\\/publications\\\/procalcitonin-guided-decision-and-antibiotic-treatment-duration-in-late-onset-sepsis-of-newborns-multicentre-randomised-controlled-trial-proabis\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Accueil\",\"item\":\"https:\\\/\\\/fhu-premimpact.org\\\/en\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Publications\",\"item\":\"https:\\\/\\\/fhu-premimpact.org\\\/en\\\/publications\\\/\"},{\"@type\":\"ListItem\",\"position\":3,\"name\":\"Procalcitonin-guided decision and antibiotic treatment duration in late onset sepsis of newborns: multicentre, randomised controlled trial (ProABIS)\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/fhu-premimpact.org\\\/en\\\/#website\",\"url\":\"https:\\\/\\\/fhu-premimpact.org\\\/en\\\/\",\"name\":\"FHU PREM'IMPACT\",\"description\":\"Perinatal inflammation and prematurity\",\"publisher\":{\"@id\":\"https:\\\/\\\/fhu-premimpact.org\\\/en\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/fhu-premimpact.org\\\/en\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/fhu-premimpact.org\\\/en\\\/#organization\",\"name\":\"FHU PREM'IMPACT\",\"url\":\"https:\\\/\\\/fhu-premimpact.org\\\/en\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/fhu-premimpact.org\\\/en\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/fhu-premimpact.org\\\/wp-content\\\/uploads\\\/2025\\\/03\\\/logo-grand-centre-fhupremimpact.jpg\",\"contentUrl\":\"https:\\\/\\\/fhu-premimpact.org\\\/wp-content\\\/uploads\\\/2025\\\/03\\\/logo-grand-centre-fhupremimpact.jpg\",\"width\":1280,\"height\":720,\"caption\":\"FHU PREM'IMPACT\"},\"image\":{\"@id\":\"https:\\\/\\\/fhu-premimpact.org\\\/en\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.instagram.com\\\/fhupremimpact\\\/\",\"https:\\\/\\\/www.linkedin.com\\\/in\\\/fhu-prem-impact-ap-hp-inserm-universit-paris-cit-70b911253\\\/\"]}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Procalcitonin-guided decision and antibiotic treatment duration in late onset sepsis of newborns: multicentre, randomised controlled trial (ProABIS) - FHU Prem'IMPACT","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/fhu-premimpact.org\/en\/publications\/procalcitonin-guided-decision-and-antibiotic-treatment-duration-in-late-onset-sepsis-of-newborns-multicentre-randomised-controlled-trial-proabis\/","og_locale":"en_US","og_type":"article","og_title":"Procalcitonin-guided decision and antibiotic treatment duration in late onset sepsis of newborns: multicentre, randomised controlled trial (ProABIS) - FHU Prem'IMPACT","og_description":"Abstract Objective: To assess whether procalcitonin-guided decision making can safely reduce the duration of antibiotic treatment in neonatal late onset sepsis. Design: Prospective multicentre, randomised open label trial. Setting: 33 level 3 and level 2B neonatology departments in France. Participants: Newborn babies born after 24 weeks’ gestation, of postconceptional age 24-45 weeks and after 4 […]","og_url":"https:\/\/fhu-premimpact.org\/en\/publications\/procalcitonin-guided-decision-and-antibiotic-treatment-duration-in-late-onset-sepsis-of-newborns-multicentre-randomised-controlled-trial-proabis\/","og_site_name":"FHU Prem'IMPACT","article_modified_time":"2026-06-05T13:47:36+00:00","twitter_card":"summary_large_image","twitter_misc":{"Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"WebPage","@id":"https:\/\/fhu-premimpact.org\/en\/publications\/procalcitonin-guided-decision-and-antibiotic-treatment-duration-in-late-onset-sepsis-of-newborns-multicentre-randomised-controlled-trial-proabis\/","url":"https:\/\/fhu-premimpact.org\/en\/publications\/procalcitonin-guided-decision-and-antibiotic-treatment-duration-in-late-onset-sepsis-of-newborns-multicentre-randomised-controlled-trial-proabis\/","name":"Procalcitonin-guided decision and antibiotic treatment duration in late onset sepsis of newborns: multicentre, randomised controlled trial (ProABIS) - FHU Prem'IMPACT","isPartOf":{"@id":"https:\/\/fhu-premimpact.org\/en\/#website"},"datePublished":"2026-05-17T13:42:41+00:00","dateModified":"2026-06-05T13:47:36+00:00","breadcrumb":{"@id":"https:\/\/fhu-premimpact.org\/en\/publications\/procalcitonin-guided-decision-and-antibiotic-treatment-duration-in-late-onset-sepsis-of-newborns-multicentre-randomised-controlled-trial-proabis\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/fhu-premimpact.org\/en\/publications\/procalcitonin-guided-decision-and-antibiotic-treatment-duration-in-late-onset-sepsis-of-newborns-multicentre-randomised-controlled-trial-proabis\/"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/fhu-premimpact.org\/en\/publications\/procalcitonin-guided-decision-and-antibiotic-treatment-duration-in-late-onset-sepsis-of-newborns-multicentre-randomised-controlled-trial-proabis\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Accueil","item":"https:\/\/fhu-premimpact.org\/en\/"},{"@type":"ListItem","position":2,"name":"Publications","item":"https:\/\/fhu-premimpact.org\/en\/publications\/"},{"@type":"ListItem","position":3,"name":"Procalcitonin-guided decision and antibiotic treatment duration in late onset sepsis of newborns: multicentre, randomised controlled trial (ProABIS)"}]},{"@type":"WebSite","@id":"https:\/\/fhu-premimpact.org\/en\/#website","url":"https:\/\/fhu-premimpact.org\/en\/","name":"FHU PREM'IMPACT","description":"Perinatal inflammation and prematurity","publisher":{"@id":"https:\/\/fhu-premimpact.org\/en\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/fhu-premimpact.org\/en\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/fhu-premimpact.org\/en\/#organization","name":"FHU PREM'IMPACT","url":"https:\/\/fhu-premimpact.org\/en\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/fhu-premimpact.org\/en\/#\/schema\/logo\/image\/","url":"https:\/\/fhu-premimpact.org\/wp-content\/uploads\/2025\/03\/logo-grand-centre-fhupremimpact.jpg","contentUrl":"https:\/\/fhu-premimpact.org\/wp-content\/uploads\/2025\/03\/logo-grand-centre-fhupremimpact.jpg","width":1280,"height":720,"caption":"FHU PREM'IMPACT"},"image":{"@id":"https:\/\/fhu-premimpact.org\/en\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.instagram.com\/fhupremimpact\/","https:\/\/www.linkedin.com\/in\/fhu-prem-impact-ap-hp-inserm-universit-paris-cit-70b911253\/"]}]}},"uagb_featured_image_src":{"full":false,"thumbnail":false,"medium":false,"medium_large":false,"large":false,"1536x1536":false,"2048x2048":false,"post-thumbnail":false,"twentytwenty-fullscreen":false},"uagb_author_info":{"display_name":"Laurence Lecomte","author_link":"https:\/\/fhu-premimpact.org\/en\/author\/"},"uagb_comment_info":0,"uagb_excerpt":"Abstract Objective: To assess whether procalcitonin-guided decision making can safely reduce the duration of antibiotic treatment in neonatal late onset sepsis. Design: Prospective multicentre, randomised open label trial. Setting: 33 level 3 and level 2B neonatology departments in France. Participants: Newborn babies born after 24 weeks’ gestation, of postconceptional age 24-45 weeks and after 4…","_links":{"self":[{"href":"https:\/\/fhu-premimpact.org\/en\/wp-json\/wp\/v2\/publication\/9394","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/fhu-premimpact.org\/en\/wp-json\/wp\/v2\/publication"}],"about":[{"href":"https:\/\/fhu-premimpact.org\/en\/wp-json\/wp\/v2\/types\/publication"}],"wp:attachment":[{"href":"https:\/\/fhu-premimpact.org\/en\/wp-json\/wp\/v2\/media?parent=9394"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}